AbbVie is your latest spinoff winner

Article Excerpt

We continue to see attractive investment opportunities for our subscribers in drug stocks—and we’re adding the best of them to your Power Growth Investor. That includes AbbVie Inc. Meanwhile, over the years, we’ve found that spinoffs are about as close as you can get to a sure thing in investing. It’s a key reason why we think AbbVie has further gains ahead for investors. ABBVIE INC., $97.70, is a buy. The company (New York symbol ABBV; TSINetwork Rating: Above Average) (www.abbvie.com; Shares outstanding: 1.8 billion; Market cap: $171.7 billion; Dividend yield: 4.8%) was formed on January 3, 2013, when Abbott Laboratories (symbol ABT on New York) split into two publicly traded companies. Under the terms of the breakup, Abbott handed out shares of AbbVie to its shareholders in a tax-free transaction—that is, shareholders will only pay capital-gains taxes on their new AbbVie shares if they sell them. Since its spinoff from Abbott Laboratories, AbbVie has depended heavily on its Humira drug to drive its growth in…